Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 15 March 2026
Revised 24 April 2026
Accepted 16 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 480–487

KEYWORDS:
Fermented turmeric; Metabolic syndrome; Inflammation; Curcumin; Functional dairy; High-sensitivity C-reactive protein; Lactobacillus; HOMA-IR; Inflammatory biomarkers; Fermented milk.

Effects of Fermented Turmeric Milk on Inflammatory Biomarkers in Metabolic Syndrome

Muninathan N[1], Shehwar Majid Kaul[2], Savlabek Kistaubayev[3], Sumanth Kumar B[4], Sheetal Sharma[5], Aakash Sharma[6], K. Ezhil Vendhan[7]

[1] Central Research Laboratory, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, muninathan@maher.ac.in
[2] Department of General Surgery, Noida International University, Greater Noida, Uttar Pradesh 203201, India, drshehwarkoul@gmail.com
[3] Department of Social Sciences, Jizzakh State Pedagogical University, savlabekkistaubayev@gmail.com
[4] Bio Chemistry, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, sumanthkumarb@maher.ac.in
[5] Department of Pharmacy, Vivekananda Global University, Jaipur, India, sheetal.sharma@vgu.ac.in
[6] Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India, aakash.sharma.orp@chitkara.edu.in
[7] Department of Ophthalmology, Vinayaka Mission's Kirupananda Variyar Medical College & Hospitals, Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India, hospitalleye@gmail.com

ABSTRACT:

Background: A food-based fermented intervention could improve adherence compared with capsule supplementation.

Objective: To evaluate fermented low-fat milk containing standardized turmeric and Lactobacillus culture in comparison with matched fermented milk without turmeric using a randomized controlled trial.

Methods: The draft protocol included 84 experimental units or participants involving adults with metabolic syndrome. The intervention was administered or tested for 12 weeks. The primary outcome was high-sensitivity C-reactive protein, with additional assessment of interleukin-6, HOMA-IR, triglycerides, waist circumference. Standardized laboratory, clinical, or food-analysis procedures were applied, and between-condition effects were evaluated with two-sided tests at $\alpha=0.05$.

Results: Fermented turmeric milk reduced hs-CRP by 35.4% from 4.8 ± 1.2 to 3.1 ± 1.0 mg/L, whereas the control changed by 6.4% (between-group $p<0.001$). HOMA-IR decreased by 0.8 units and triglycerides by 22 mg/dL in the turmeric group; adherence was 93.2% and no serious adverse events occurred. The direction and magnitude of the

Natural Resources for Human Health
eISSN: 2583-1194

dummy findings were internally consistent across primary and secondary endpoints, and tolerability or assay-quality criteria remained acceptable.

Conclusion: The example dataset suggests that fermented low-fat milk containing standardized turmeric and Lactobacillus culture could produce a meaningful improvement in high-sensitivity C-reactive protein through enhanced curcuminoid biotransformation during fermentation and modulation of inflammatory-metabolic signaling. These findings are intended solely as a complete manuscript-development example and require replacement with ethically generated, independently verified observations before scientific submission.

1. INTRODUCTION

Effects of Fermented Turmeric Milk on Inflammatory Biomarkers in Metabolic Syndrome addresses an important question at the interface of experimental pharmacology, nutritional science, and translational health research. Directly relevant published work has established a scientific basis for evaluating fermented low-fat milk containing standardized turmeric and Lactobacillus culture in relation to high-sensitivity C-reactive protein [1]. Nevertheless, variations in preparation, exposure, comparator selection, and outcome definition continue to limit confident comparison across studies.

A second line of evidence supports the biological plausibility of the present hypothesis. Prior investigations of fermented turmeric and closely related interventions have reported functional or biochemical activity that is consistent with the proposed direction of benefit [2]. Such observations justify the formal testing, but do not exclude the use of standardized materials and pre-defined criteria of analysis.

Reproducibility relies on chemical characterization, processing conditions, dose, biological matrix and stability of active constituents have been found in the wider natural-product and functional-food literature [3]. In the current investigation, fermented low-fat milk with a standardized amount of turmeric and Lactobacillus culture was thus considered a research grade intervention but not a random traditional or commercial preparation.

The suggested mechanism includes increased curcuminoid biotransformation in the fermentation process and inflammatory-metabolic signaling. There is published evidence that associated biological reactions typically entail linking redox, inflammatory, metabolic, microbial, enzymatic or differentiation pathways instead of a solitary target [4]. The simultaneous quantification of a primary functional endpoint and mechanistic markers can thus yield a more consistent interpretation.

The techniques used in outcome assessment also demand study model-appropriate methods. Laboratory/clinical methodology Standard procedures in the handling of samples, validated methods of analysis, adequate controls, and predefined interpretation limits are emphasized in established laboratory or clinical methodology [5]. These criteria were used to select high-sensitivity C-reactive protein as the main endpoint and the secondary ones.

When interleukin-6 and HOMA-IR change concordantly with the change in high-sensitivity C-reactive protein, changes in the latter are most compelling. Related studies have also revealed the importance of incorporating functional, biochemical and structural results in the assessment of complex botanical, microbial or food-based interventions [6].

Quality and safety are also very important. Natural origin does not imply constant composition and lack of adverse effects, contaminants, interactions or degradation, and published pharmacovigilance and quality-control data suggest that these factors should be considered early in product development [7].

Lastly, study design should be made transparent to minimize bias. Randomization, blinding (where possible), replication, full description of exclusions, and reporting of effect estimates and not use of p-values alone are guided and supported by prior methodological research applicable to the current experimental model [8].

In spite of the evidence, there are limited studies that have incorporated a well defined fermented low fat milk with standardized turmeric and Lactobacillus culture, an appropriate comparator, a prespecified primary endpoint, and supporting mechanistic or feasibility outcomes in adults with metabolic syndrome. The objective of this research was thus to identify how fermented low-fat milk in which the turmeric was standardized and that which contained Lactobacillus culture affected high-sensitivity C-reactive protein relative to comparable fermented milk without turmeric. Secondary aims were to measure interleukin-6, HOMA-IR, triglycerides and other quality or safety measures.

2. MATERIALS AND METHODS

2.1. Study design and setting

The prespecified randomized parallel-group controlled trial that is described in this manuscript entails metabolic syndrome adults. The designed sample size was 84 experimental units or participants and was designed to compare fermented low-fat milk with standardized turmeric culture and Lactobacillus culture with fermented milk without turmeric. The time of observation was 12 weeks. Any numerical values in this manuscript are dummy/example numbers generated to draft, statistically demonstrate, and construct tables and create graphs; they are not observations of an actual experimental investigation completed. Design still adheres to realistic laboratory or clinical procedures such that the draft could be later translated to an approved protocol and substituted with actual measurements.

2.2. Participants

Potential subjects were adults or adolescents who fit the target population: adults with metabolic syndrome. The inclusion criteria were a steady health or steady background care, readiness to continue regular diet and exercise, and ability to be present at all assessment visits. The exclusion criteria were being pregnant, having a major organ disease, having used antibiotic or probiotics within the last three months, having taken supplements that might affect the primary endpoint, allergic to study components, or having enrolled in another intervention study. A real trial would necessitate written informed consent and (where necessary) assent and guardian consent.

2.3. Randomization, allocation, and intervention

The participants were randomly assigned by a 1:1 ratio with variable block sizes, and an allocation was blinded in sequentially numbered opaque envelopes or an electronic system. The intervention group was fermented with low-fat milk mixed with standardized turmeric and Lactobacillus culture; the control group was fermented with an equal amount of fermented milk without turmeric. The goods were packed in codified packages and had the similar looks and instructions. They were instructed to continue with habitual diet, medication and physical activity and adherence was estimated by counting unused products and recording daily records.

2.4. Outcome assessment

High-sensitivity C-reactive protein (mg/L) was the primary outcome; interleukin-6, HOMA-IR, triglycerides, waist circumference were secondary outcomes. The design planned to measure the baseline and follow-up or across concentration and time conditions. Assays were conducted based on either approved kit protocols or standardized analysis procedures, and repeat measurements were done whenever the coefficient of variation was greater than 10%. Clinical measurements were recorded following a standardized rest period and the outcome of food-products was tested under controlled serving conditions.

2.5. Quality assurance and bias control

Laboratory / trial manual This was a written protocol of how the samples would be labeled, when they would be taken, calibration, data entry and protocol deviations. Blinding was done whenever possible by outcome assessors. Conceptual rechecking of ten percent of records was done against the source data and the acceptable analytical runs were not accepted till the limits of calibration and quality-control samples were met. Missing values were not filled in where the main complete-case presentation; sensitivity analyses employed an intention-to-treat framework or model-based estimation where needed.

2.6. Sample-size rationale

The 84 units were planned to give a realistic precision in developing a manuscript. To use in a real study, the calculation will be substituted by a calculation using a pilot-derived standard deviation and the smallest difference in high-sensitivity C-reactive

protein which is clinically or biologically significant. The last calculation must mention two-sided α=0.05, required power of at least 80%, allocation ratio, expected attrition or unusable assays and whether to adjust due to repeated measures or clustering or multiple primary comparisons.

2.7. Statistical analysis

When data were approximately normally distributed they were summarized as mean ± standard deviation; when skewed, they were summarized as median with interquartile range. Categorical data were presented as number and percentage. The baseline comparison between groups were analyzed by independent t test, Mann Whitney test, chi-square and/or Fisher exact test, depending on the type of data. Primary outcomes were evaluated using analysis of covariance, repeated-measures analysis, mixed-effects modeling, one-way analysis of variance with multiplicity adjusted post hoc comparisons or by nonparametric equivalents as appropriate, depending on the design. Effect estimates were accompanied by 95% confidence intervals. Pearson's or Spearman's correlation coefficients were used. The tests were two-sided and the level of significance was set at $p<0.05$. Conceptual analyses were generated in an existing statistical package that included an auditable syntax file.

3. RESULTS

The entire Dummy/Example data set provided for the randomized parallel-group controlled trial was analyzed. No quality-control run was rejected and baseline characteristics and assay controls were comparable across comparison conditions. The tables present mean ± standard deviation unless another summary is stated. Because the data are illustrative, participant flow, assay exclusions, and p-values were generated to be statistically coherent rather than to represent an actual enrolled sample.

Fermented turmeric milk reduced hs-CRP by 35.4% from 4.8 ± 1.2 to 3.1 ± 1.0 mg/L, whereas the control changed by 6.4% (between-group $p<0.001$).

Table 1. Baseline characteristics

Characteristic	Intervention	Control	p-value
Participants (n)	42	42	—
Age (years)	45.8 ± 7.4	44.1 ± 7.1	0.78
Female n (%)	23 (56.0)	23 (55.0)	0.91
BMI (kg/m²)	27.8 ± 2.9	27.6 ± 3.1	0.74
Primary endpoint at baseline	4.8 ± 1.1	4.7 ± 1.1	0.83

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The direction of the primary effect was supported by changes in interleukin-6 and HOMA-IR. The magnitude of response generally increased with intervention exposure or was greater at follow-up in the intervention arm, while the comparator showed smaller changes. Where repeated measurements were available, the group-by-time or condition effect remained significant after adjustment for baseline values and planned multiple comparisons.

Table 2. Primary and key secondary outcomes

Outcome	Intervention baseline	Intervention end	Control baseline	Control end	p for interaction
hs-CRP (mg/L)	4.8 ± 0.6	3.1 ± 0.5	4.7 ± 0.6	4.4 ± 0.5	<0.001
IL-6 (pg/mL)	5.9 ± 0.6	4.2 ± 0.4	5.8 ± 0.6	5.5 ± 0.6	0.003
triglycerides	100 ± 12	86 ± 11	99 ± 13	96 ± 12	0.011

Values are dummy/example data presented as mean ± SD unless otherwise stated.

HOMA-IR decreased by 0.8 units and triglycerides by 22 mg/dL in the turmeric group; adherence was 93.2% and no serious adverse events occurred.



Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses indicated that the response in high-sensitivity C-reactive protein was associated with the most relevant mechanistic marker. The pattern was consistent with enhanced curcuminoid biotransformation during fermentation and modulation of inflammatory-metabolic signaling. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Adherence, acceptability, and safety

Outcome	Intervention	Control	p-value
Adherence (%)	92.4 ± 5.8	91.7 ± 6.1	0.58
Overall acceptability / 9	7.4 ± 0.8	7.6 ± 0.7	0.21
Mild gastrointestinal events n (%)	3 (7.1)	2 (4.8)	0.64
Serious adverse events	0	0	—
Participants completing study	40 (95.2)	40 (95.2)	0.98

Values are dummy/example data presented as mean ± SD unless otherwise stated.



Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that fermented low-fat milk containing standardized turmeric and Lactobacillus culture may improve high-sensitivity C-reactive protein compared with matched fermented milk without turmeric. The dummy findings were strengthened by concordant changes in interleukin-6, HOMA-IR, and triglycerides. This internal consistency is important because agreement across functional and mechanistic endpoints is less likely to reflect isolated analytical variation.

The direction of the primary result is broadly consistent with additional published research on standardized botanical or food-derived interventions in related models [9]. That literature also shows that, in some circumstances, the quality of preparation and the dose can significantly affect the magnitude of the response, if that is not the case, the protocols are different and the populations are different.

Similar studies have also indicated changes in inflammatory, oxidative, metabolic, microbial, structural or functional parameters, favoring a multidimensional evaluation, instead of a single surrogate parameter [10]. The current form thus represents a broader evidence base, but is specific to the intervention and model explored in this study.

Research has shown that complex interventions can have matrix-dependent effects and convergent pathways [11]. Which support the mechanistic interpretation. The correlation between the primary response and supporting markers was found to be consistent with improved production of circuminoids during fermentation, and with modulation of inflammatory-metabolic signaling, but does not prove mediation and cannot identify the active constituent.

Further evidence of clinical/biological importance of IL-6 and HOMA-IR has been shown in previous studies with similar endpoints [12]. This parallel improvement supports the hypothesis, but further confirmatory studies would benefit by having these variables pre-specified as secondary outcomes and/or as mechanistic mediators or exploratory biomarkers.

The size of the example effect should be considered in light of previous intervention studies and evidence syntheses in the wider domain [13]. The magnitude was designed to be realistic, and overlap between persons or replicates, as pilot effects often are reduced in larger independent samples.

The methodological evidence highlights the need for studies of complex interventions to be standardised in their measurement, conditions for comparison, and reporting [14]. Bias can be minimised by replication, allocation concealment, blinded assessment, crossover control or validated analytical calibration, but not all sources of bias can be eliminated.

Tolerability, quality assurance, product stability, adherence, and interactions with the diet or other medications used by the user are additional factors that have to be considered for long term translation. There are published safety and implementation

literature that provide support for measuring these factors in tandem with efficacy, not once a positive primary outcome has been achieved [15].

There are a number of limitations in the study. First, the numbers in the data set DO NOT make a scientific claim. Secondly, the proposed sample and length of time may not capture rare adverse events or adaptation over time. Third, surrogate outcomes may not be considered patient important benefits. Fourth, there may be dietary, genetic, microbial, environmental, harvest or manufacturing factors that are not measured that can modify response.

More work should be done and involve independent analytical confirmation, dose ranging, preregistration, sufficient sample size, and a prespecified statistical analysis plan. Ethics approval, trial registration, allocation procedures, adherence and ITT analysis should be documented in clinical studies. Randomization, blinding, humane endpoints, exclusions and batch level chemical fingerprints should all be reported in preclinical studies.

Translationally, a food based fermented intervention may be more palatable to the patients than capsule supplementation. The intervention must not be used as a substitute for existing care - it should be used as a potential adjunct or research lead. Further development should be considered in terms of the following: replication, safety, cost, standardisation, acceptability, and comparison with existing alternatives.

As a whole, the results of the example findings are supportive of the study hypothesis and offer a logical framework for a valid investigation. Any number, statement of ethics, registration information, disclosure, and analysis should be replaced or checked against the study record before submitting it to scientific journals.

5. CONCLUSION

The fermented low-fat milk group fed standardized turmeric and Lactobacillus culture had a favorable effect on high-sensitivity C-reactive protein, along with a favorable effect on interleukin-6, HOMA-IR, and triglycerides in this complete manuscript draft using dummy/example data. The pattern was in line with an augmentation of the biotransformation of the cumuninoids during fermentation and modulation of inflammatory-metabolic signaling, and hinted at potential relevance as a food-based fermented intervention would likely offer better adherence advantage than capsule supplementation. The draft should serve as a framework from which protocol development, planning for data collection, and manuscript preparation will follow, but all numerical results need to be replaced with ethically generated and independently verified data before it can be portrayed as original research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Marco ML, Heeney D, Binda S, et al. Health benefits of fermented foods: microbiota and beyond. Curr Opin Biotechnol. 2017;44:94-102. doi:10.1016/j.copbio.2016.11.010. PMID:27998788.

[2] Yong CC, Yoon Y, Yoo HS, Oh S. Effect of Lactobacillus fermentation on anti-inflammatory potential of turmeric. J Microbiol Biotechnol. 2019;29(10):1561-1569. doi:10.4014/jmb.1906.06032. PMID:31434176.

[3] Ulven SM, Holven KB, Gil A, Rangel-Huerta OD. Milk and dairy product consumption and inflammatory biomarkers: an updated systematic review of randomized clinical trials. Adv Nutr. 2019;10(suppl_2):S239-S250. doi:10.1093/advances/nmy072. PMID:31089732.

[4] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.

[5] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9. PMID:30638909.

[6] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[7] Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66. PMID:24912386.

[8] Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502. doi:10.1038/nrgastro.2017.75. PMID:28611480.

[9] Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687-701. doi:10.1038/s41575-020-0344-2. PMID:32826966.

[10] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.

[11] Jenkins DJA, Wolever TMS, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362-366. doi:10.1093/ajcn/34.3.362. PMID:6259925.

[12] Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18(1):145-171. doi:10.1079/NRR2005100. PMID:19079901.

[13] Ayaz A, Akyol A, Inan-Eroglu E, Kabasakal Cetin A, Samur G, Akbiyik F. Chia seed added yogurt reduces short-term food intake and increases satiety: randomized controlled trial. Nutr Res Pract. 2017;11(5):412-418. doi:10.4162/nrp.2017.11.5.412. PMID:28989578.

[14] Ho H, Lee AS, Jovanovski E, Jenkins AL, DeSouza R, Vuksan V. Effect of whole and ground Salba seeds on postprandial glycemia in healthy volunteers: a randomized controlled dose-response trial. Eur J Clin Nutr. 2013;67(7):786-788. doi:10.1038/ejcn.2013.103.

[15] Zare M, Goli AH, Karimifar M, Tarrahi MJ, Rezaei A, Amani R. Effect of bread fortification with pomegranate peel powder on glycemic indicators, antioxidant status, inflammation and mood in patients with type 2 diabetes: study protocol for a randomized triple-blind placebo-controlled trial. J Diabetes Metab Disord. 2023;22(1):921-929. doi:10.1007/s40200-022-01168-z. PMID:36628115.